Average Manufacturer Prices For Medicaid Drugs Are Publicly Available For First Time
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS surprises industry by releasing federal upper limit drug pricing files that include weighted average manufacturer prices, without first releasing a rule on the AMP calculation.
You may also be interested in...
CMS’ Long-Awaited AMP Rule Seeks To Clarify Uncertainties In Affordable Care Act’s Definition
A proposed rule on the calculation of average manufacturer price issued Jan. 27 addresses numerous complex issues for the pharmaceutical industry in its 200 pages, including a proposal that manufacturers report AMP based on their actual sales to retail community pharmacies or to wholesalers for drugs distributed to retail community pharmacies.
A Return To Restricted Pharmacy Networks Leaves NCPA Concerned
In an interview, National Community Pharmacists Association CEO Doug Hoey expresses concern with restricted pharmacy networks in health plans as well as a lack of clarity about those restricted networks on the Medicare Part D Plan Finder website.
Pharmacy Groups Say Draft Medicaid FULs Could Lead To Rx Access Issues
Associations representing retail pharmacies say faults in CMS’ draft average manufacturer price-based federal upper limits for multiple source drugs could result in reduced access to drugs by the Medicaid population.